Arcus Biosciences, Inc. (RCUS)Â
Trading
Quantity
Profitability
Ownership
Largest Insider Buys in Sector
RCUS Insider Trading Activity
RCUS Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $15,402,661 | 3 | 43 |
Sells | $280,024 | 4 | 57 |
Related Transactions
| GILEAD SCIENCES, INC. | 10 percent owner | 1 | $15M | 0 | $0 | $15M |
| ROSEN TERRY J | Chief Executive Officer | 1 | $201,465 | 0 | $0 | $201,465 |
| KANEKO YASUNORI | director | 1 | $201,200 | 0 | $0 | $201,200 |
| Azoy Alexander | Chief Accounting Officer | 0 | $0 | 2 | $23,394 | $-23,394 |
| Goeltz II Robert C. | Chief Financial Officer | 0 | $0 | 1 | $53,910 | $-53,910 |
| Jarrett Jennifer | Chief Operating Officer | 0 | $0 | 1 | $202,720 | $-202,720 |
About Arcus Biosciences, Inc.
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; Quemliclustat, a small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer; and AB521, an oral and small molecule HIF-2a inhibitor that is in Phase 1 study for the treatment of patients with von Hippel- Lindau disease. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca, BVF Partners L.P to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California.
Insider Activity of Arcus Biosciences, Inc.
Over the last 12 months, insiders at Arcus Biosciences, Inc. have bought $15.4M and sold $280,024 worth of Arcus Biosciences, Inc. stock.
On average, over the past 5 years, insiders at Arcus Biosciences, Inc. have bought $144.25M and sold $2.4M worth of stock each year.
Highest buying activity among insiders over the last 12 months: GILEAD SCIENCES, INC. (10 percent owner) — $15M. ROSEN TERRY J (Chief Executive Officer) — $201,465. KANEKO YASUNORI (director) — $201,200.
The last purchase of 19,800 shares for transaction amount of $201,465 was made by ROSEN TERRY J (Chief Executive Officer) on 2025‑02‑27.
List of Insider Buy and Sell Transactions, Arcus Biosciences, Inc.
| 2025-02-27 | ROSEN TERRY J | Chief Executive Officer | 19,800 0.0191% | $10.18 | $201,465 | -3.19% | ||
| 2025-02-27 | KANEKO YASUNORI | director | 20,000 0.019% | $10.06 | $201,200 | -3.19% | ||
| 2025-02-18 | GILEAD SCIENCES, INC. | 10 percent owner | 1.36M 1.2512% | $11.00 | $15M | -11.35% | ||
| 2024-12-31 | Sale | Goeltz II Robert C. | Chief Financial Officer | 3,594 0.004% | $15.00 | $53,910 | -16.05% | |
| 2024-12-02 | Sale | Azoy Alexander | Chief Accounting Officer | 201 0.0002% | $15.32 | $3,079 | -16.22% | |
| 2024-08-13 | Sale | Azoy Alexander | Chief Accounting Officer | 1,357 0.0015% | $14.97 | $20,314 | -1.15% | |
| 2024-03-27 | Sale | Jarrett Jennifer | Chief Operating Officer | 11,551 0.0123% | $17.55 | $202,720 | -14.33% | |
| 2024-03-18 | Sale | Jarrett Jennifer | Chief Operating Officer | 13,449 0.0154% | $17.92 | $240,941 | -9.06% | |
| 2024-02-27 | Sale | Jaen Juan C. | President | 23,132 0.0255% | $20.10 | $464,953 | -21.66% | |
| 2024-02-27 | Sale | Jarrett Jennifer | Chief Operating Officer | 34,070 0.0376% | $20.11 | $685,148 | -21.66% | |
| 2024-02-26 | Sale | Jaen Juan C. | President | 3,900 0.0044% | $20.06 | $78,234 | -19.48% | |
| 2024-02-26 | Sale | Jarrett Jennifer | Chief Operating Officer | 24,555 0.0276% | $20.07 | $492,819 | -19.48% | |
| 2024-01-29 | GILEAD SCIENCES, INC. | 10 percent owner | 15.24M 28.0689% | $21.00 | $320M | +4.25% | ||
| 2024-01-02 | Sale | Jaen Juan C. | President | 6,975 0.0096% | $20.09 | $140,128 | -17.94% | |
| 2024-01-02 | Sale | Goeltz II Robert C. | Chief Financial Officer | 2,004 0.0027% | $20.00 | $40,080 | -17.94% | |
| 2023-12-22 | Sale | Jarrett Jennifer | Chief Operating Officer | 21,521 0.028% | $17.76 | $382,213 | -10.19% | |
| 2023-12-01 | Sale | Azoy Alexander | Chief Accounting Officer | 282 0.0004% | $14.95 | $4,216 | +1.34% | |
| 2023-09-22 | Sale | Jarrett Jennifer | Chief Operating Officer | 21,369 0.0291% | $19.99 | $427,166 | -18.08% | |
| 2023-07-28 | Sale | Jarrett Jennifer | Chief Operating Officer | 45,000 0.0639% | $20.25 | $911,250 | -17.54% | |
| 2023-07-03 | Sale | Azoy Alexander | Chief Accounting Officer | 1,018 0.0014% | $20.41 | $20,777 | -17.56% |
Insider Historical Profitability
| GILEAD SCIENCES, INC. | 10 percent owner | 31424760 29.6905% | $280.94M | 4 | 0 | <0.0001% |
| ROSEN TERRY J | Chief Executive Officer | 2554160 2.4132% | $22.83M | 22 | 6 | <0.0001% |
| Jarrett Jennifer | Chief Operating Officer | 215253 0.2034% | $1.92M | 0 | 24 | |
| Goeltz II Robert C. | Chief Financial Officer | 60138 0.0568% | $537,633.72 | 1 | 6 | +33.11% |
| KANEKO YASUNORI | director | 28400 0.0268% | $253,896.00 | 2 | 0 | <0.0001% |
| Azoy Alexander | Chief Accounting Officer | 19070 0.018% | $170,485.80 | 0 | 4 | |
| Jaen Juan C. | President | 1188233 1.1227% | $10.62M | 8 | 9 | <0.0001% |
| FALBERG KATHRYN E | director | 102106 0.0965% | $912,827.64 | 7 | 0 | +8.71% |
| Tang Carolyn C. | General Counsel | 28584 0.027% | $255,540.96 | 0 | 6 | |
| Grossman William | Chief Medical Officer | 20723 0.0196% | $185,263.62 | 3 | 5 | +93.38% |
Historical Insider Profitability vs. Competitors
$54,590,806 | 65 | 21.84% | $1.19B | |
Arcus Biosciences, Inc. (RCUS) | $571,084,134 | 44 | 4.33% | $946.22M |
$97,176 | 41 | 42.84% | $828.53M | |
$530,111,731 | 35 | 8.67% | $1.08B | |
$28,907,358 | 35 | 41.41% | $930.1M | |
$61,752,931 | 34 | 14.31% | $894.39M | |
$7,598,498 | 27 | 34.68% | $1.17B | |
$169,638,586 | 22 | 30.82% | $1.16B | |
$1,272,896 | 16 | 24.56% | $1.16B | |
$104,137,421 | 15 | 21.28% | $898.89M | |
$50,317,062 | 13 | -3.69% | $885.02M | |
$103,194,328 | 13 | 9.02% | $834.15M | |
$278,247,340 | 12 | 58.08% | $950.4M | |
$20,499,451 | 9 | 71.54% | $815.17M | |
$2,834,855 | 9 | 34.92% | $1.18B | |
$49,165,200 | 7 | 12.92% | $833.3M | |
$1,229,547 | 7 | 11.98% | $1.16B | |
$46,235,722 | 6 | -31.77% | $931.65M | |
$7,605,533 | 5 | 17.10% | $1.06B |
RCUS Institutional Investors: Active Positions
| Increased Positions | 88 | +41.31% | 37M | +67.95% |
| Decreased Positions | 89 | -41.78% | 5M | -9.14% |
| New Positions | 26 | New | 34M | New |
| Sold Out Positions | 24 | Sold Out | 550,903 | Sold Out |
| Total Postitions | 212 | -0.47% | 87M | +58.81% |
RCUS Ownership Change vs Market
Institutional Investor Ownership
| Gilead Sciences, Inc. | $280,771.00 | 28.36% | 30.06M | +30M | New | 2024-12-31 |
| Blackrock, Inc. | $90,544.00 | 9.15% | 9.69M | -38,137 | -0.39% | 2024-12-31 |
| Vanguard Group Inc | $50,335.00 | 5.08% | 5.39M | -79,539 | -1.45% | 2024-12-31 |
| Fmr Llc | $37,851.00 | 3.82% | 4.05M | -415,036 | -9.29% | 2024-12-31 |
| Woodline Partners Lp | $32,914.00 | 3.32% | 3.52M | +45,497 | +1.31% | 2024-12-31 |
| State Street Corp | $27,961.00 | 2.82% | 2.99M | -17,445 | -0.58% | 2024-12-31 |
| Point72 Asset Management, L.P. | $18,645.00 | 1.88% | 2M | -440,794 | -18.09% | 2024-12-31 |
| Dimensional Fund Advisors Lp | $15,900.00 | 1.61% | 1.7M | +178,351 | +11.7% | 2024-12-31 |
| Siren, L.L.C. | $15,057.00 | 1.52% | 1.61M | 0 | 0% | 2024-12-31 |
| Invus Financial Advisors, Llc | $15,057.00 | 1.52% | 1.61M | 0 | 0% | 2024-06-30 |